Revumenib
A small molecule inhibitor used in cancer treatment
| Revumenib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Revumenib is a small molecule inhibitor that targets the menin-MLL interaction, which is implicated in certain types of acute leukemia. It is primarily being investigated for its potential use in treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with specific genetic mutations.
Mechanism of Action[edit | edit source]
Revumenib functions by inhibiting the interaction between menin, a protein that plays a role in gene expression regulation, and the mixed-lineage leukemia (MLL) protein. This interaction is crucial in the pathogenesis of leukemias that harbor MLL rearrangements. By disrupting this interaction, revumenib can potentially halt the proliferation of leukemic cells and induce differentiation.
Clinical Development[edit | edit source]
Revumenib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with MLL-rearranged leukemias. These trials aim to determine the optimal dosing regimen and to assess the drug's impact on survival rates and disease progression.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of revumenib includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to be orally bioavailable, allowing for convenient administration. The drug's metabolism and elimination pathways are being studied to optimize its therapeutic window and minimize potential side effects.
Potential Side Effects[edit | edit source]
As with many targeted therapies, revumenib may cause side effects, which can include gastrointestinal disturbances, fatigue, and hematological abnormalities. Ongoing studies are focused on identifying and managing these adverse effects to improve patient outcomes.
Research and Future Directions[edit | edit source]
Research on revumenib is expanding to explore its use in combination with other therapies, such as chemotherapy and immunotherapy, to enhance its efficacy. Additionally, studies are investigating its potential application in other malignancies with similar genetic profiles.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
